Report Details:
15 Companies Covered
90 Pages
Rising Geriatric Population to Push the Osteoarthritis Market at a Strong CAGR of 9.12% During the Forecast Period 2025-2035
Market Overview
The global osteoarthritis market was valued at USD 5.12 billion in 2024 and is projected to reach USD 13.37 billion by 2035, registering a 9.12% CAGR from 2025 to 2035.
The market growth is driven by the rising geriatric population, increased prevalence of obesity, growing sedentary lifestyles, and strong demand for minimally invasive and non-invasive therapies.
Increasing awareness campaigns, higher diagnosis rates, and continuous advancements in pain management and regenerative treatments are accelerating market adoption across both developed and emerging economies.
Osteoarthritis is one of the most common degenerative joint diseases, affecting the knee, hip, and spinal joints. The disease significantly lowers mobility and quality of life, resulting in higher demand for sustained pain relief medication, advanced imaging diagnostics, and improved therapeutic procedures.
The integration of regenerative medicine, which includes platelet-rich plasma (PRP) therapy, stem cell treatment, and biologics, is becoming increasingly important, supporting market growth as healthcare providers shift toward long-term disease-modifying solutions instead of traditional pain-suppression protocols.
Segment Insights
By type, the market is segmented into hip osteoarthritis and spinal osteoarthritis. Spinal osteoarthritis held the major share in 2022. Rising obesity prevalence, a sedentary lifestyle, and increasing cases of spinal degeneration among aging populations are key contributors to segment dominance.
By diagnosis, the market includes imaging and joint fluid analysis. Imaging dominated the market in 2022 and is likely to remain the fastest-growing diagnosis method through 2035.
Radiography remained the primary imaging modality for osteoarthritis management, while MRI and ultrasound are utilized for complex or rapidly progressing cases.
By treatment, the market is segmented into medication, surgery, and therapy. Medication held the largest share in 2022 and is projected to grow fastest through 2035 due to the increased use of NSAIDs, higher prescription rates, and new product launches.
Growing R&D in viscosupplementation and government initiatives supporting drug innovation are driving treatment advancements.
By end user, the market is segmented into hospitals and medical institutes. Hospitals were the largest contributor in 2022 and are expected to maintain dominance due to growing patient inflow, improved healthcare infrastructure, and support from government-funded research programs.
Regional Insights
The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.
North America accounted for USD 1.96 billion in 2022, with a 45.80% share, driven by rising osteoarthritis prevalence, strong healthcare expenditure, and adoption of advanced treatment options. Pharmaceutical companies are heavily investing in R&D, and the presence of major market players further supports regional market leadership.
Europe represents the second-largest market, supported by the high prevalence of knee osteoarthritis, growing clinical trials, strong availability of advanced research facilities, and accelerated drug approvals.
The UK holds the largest market share in this region, while Germany is the fastest-growing market. Asia-Pacific is forecast to grow at the fastest CAGR through 2035.
Rising geriatric population, increasing demand for advanced osteoarthritis treatments, expanding healthcare investments, and supportive government initiatives are positioning the region as an emerging growth hub. China holds the largest market share in the region, while India is the fastest-growing market.
Key Players
Key players operating in the global osteoarthritis market include: Abbott, Novartis AG, Pfizer Inc., Eli Lilly and Company, ABIOGEN PHARMA S.p.A, and Merck Sharp & Dohme Corp. These companies are focusing on expanding their product portfolios through new launches, collaborations, clinical studies, and regional expansions.
Industry Developments
- In March 2023, Krka announced the launch of Robexera, the first generic robenacoxib medication, used to treat pain and inflammation caused by osteoarthritis in dogs.
- In June 2023, Zydus Lifesciences received final approval from the US FDA to manufacture and market delayed-release tablets indicated for treating osteoarthritis patients at high risk of developing gastrointestinal ulcers.
- In October 2023, Abbott expanded the availability of its Voltaren pain relief portfolio across Asia-Pacific markets, strengthening its osteoarthritis consumer health segment presence.
Key Findings
- The osteoarthritis market is projected to grow from USD 5.12 billion in 2024 to USD 13.37 billion by 2035, at a CAGR of 9.12% (2025–2035).
- Imaging dominated the diagnosis segment due to its critical role in detecting disease progression.
- Medication remains the largest and fastest-growing treatment segment due to strong demand for NSAIDs and viscosupplementation therapies.
- North America led the global market with a 45.80% share, while Asia-Pacific was the fastest-growing region due to increasing healthcare spending and a large patient pool.
